Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer HIV Vaccines
NCT06267872Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer + ALFQ in human immunodeficiency virus infection (HIV) (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of local reactogenicity signs and symptoms at Day 239, Frequency of systemic reactogenicity signs and symptoms at Day 239 and 7 more. Planned start Oct 2024; status: withdrawn.
02
Drugs
CD4BS CH505M5 Pr-NP1CH505 TF chTrimer + ALFQ
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06267872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267872.